Anders Ingvarsson will leave the board in connection with the extraordinary general meeting that the board intends to convene shortly, in accordance with the press release published earlier today. Notice of the extraordinary general meeting will be published in a separate press release.

“I am pleased to note that the financing solution we have developed will facilitate the conditions for AegirBio to continue with the RADx® Tech program. It has been a great honor for me to lead the work of the board, and to work with the management and all employees. I am proud of what we have achieved and look forward to following the Company’s continued development from outside the boardroom”, says Anders Ingvarsson, Chairman of the Board of AegirBio.

This disclosure contains information that AegirBio is obliged to make public pursuant to the EU Market Abuse Regulation (EU nr 596/2014). The information was submitted for publication, through the agency of the contact person, on 09-04-2024 08:45 CET.